Sphingosine-1-phosphate receptor modulator

Priothera - FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)

Retrieved on: 
Thursday, March 3, 2022
ODD, Graft-versus-host disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Adult, HSCT, GVL, European Medicines Agency, GVHD, Food, Entrepreneurship, Safety, Sphingosine-1-phosphate receptor modulator, Modulation, FDA, EMA, LLC, Hematopoietic stem cell transplantation, Company, Allogenic succession, AML, Lymphatic system, Trial of the century, CEO, Mortality, Acute myeloid leukemia, Committee, HealthCap, COMP, Pharmaceutical industry, Vaccine

Florent Gros, Co-Founder and CEO of Priothera, commented:"The orphan drug designations we received for mocravimod from both the FDA and EMA are important milestones towards addressing the urgent, unmet needs of AML patients.

Key Points: 
  • Florent Gros, Co-Founder and CEO of Priothera, commented:"The orphan drug designations we received for mocravimod from both the FDA and EMA are important milestones towards addressing the urgent, unmet needs of AML patients.
  • Allogenic stem cell transplantation is the only potentially curative approach for AML patients but has unacceptably high mortality rates with current treatments.
  • Moreover, it has shown a clinically relevant benefit in an early clinical study in patients with hematologic malignancies undergoing HSCT.
  • Mocravimod will be investigated in a Phase 2b/3 study as a potential treatment for patients with Acute Myeloid Leukemia (AML) receiving allogeneic hematopoietic stem cell transplantation (HSCT).

Priothera - FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)

Retrieved on: 
Thursday, March 3, 2022
ODD, Graft-versus-host disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Adult, HSCT, GVL, European Medicines Agency, GVHD, Food, Entrepreneurship, Safety, Sphingosine-1-phosphate receptor modulator, Modulation, FDA, EMA, LLC, Hematopoietic stem cell transplantation, Company, Allogenic succession, AML, Lymphatic system, Trial of the century, CEO, Mortality, Acute myeloid leukemia, Committee, HealthCap, COMP, Pharmaceutical industry, Vaccine

DUBLIN, March 3, 2022 /PRNewswire/ --  Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator drug, mocravimod, today announced that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation (ODD) to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). EMA's ODD follows a recommendation from the Committee for Orphan Medicinal Products (COMP).

Key Points: 
  • Florent Gros, Co-Founder and CEO of Priothera, commented:"The orphan drug designations we received for mocravimod from both the FDA and EMA are important milestones towards addressing the urgent, unmet needs of AML patients.
  • Allogenic stem cell transplantation is the only potentially curative approach for AML patients but has unacceptably high mortality rates with current treatments.
  • Moreover, it has shown a clinically relevant benefit in an early clinical study in patients with hematologic malignancies undergoing HSCT.
  • Mocravimod will be investigated in a Phase 2b/3 study as a potential treatment for patients with Acute Myeloid Leukemia (AML) receiving allogeneic hematopoietic stem cell transplantation (HSCT).

European Commission approves PONVORYTM ▼ (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features

Retrieved on: 
Monday, May 24, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical devices, Clinical trials, Immunosuppressants, Medical specialties, Multiple sclerosis, Immunology, Medicine, Nitriles, Teriflunomide, Sphingosine-1-phosphate, Janssen Pharmaceuticals, Ponesimod, S1PR1, Sphingosine-1-phosphate receptor modulator, Multiple Sclerosis, PONVORY (ponesimod), the Janssen Pharmaceutical Companies of Johnson & Johnson, MULTIPLE SCLEROSIS, PONVORY (PONESIMOD), THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON

Janssen Research & Development, LLC, and Johnson & Johnson Middle East FZ-LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Key Points: 
  • Janssen Research & Development, LLC, and Johnson & Johnson Middle East FZ-LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a Randomized clinical trial.
  • Janssen Receives Positive CHMP Opinion for PONVORY (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features.
  • 11 DAmbrosio D, Feedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.

Global Sphingosine 1 Phosphate Receptor Modulators Pipeline Insights Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 11, 2021
Health, Pharmaceutical, G protein-coupled receptors, Arena Pharmaceuticals, Sphingosine-1-phosphate receptor modulator, Biology

b'The "Sphingosine 1 Phosphate Receptor Modulators - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Sphingosine 1 phosphate receptor modulators - Pipeline Insight, 2021 report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Sphingosine 1 phosphate receptor modulators pipeline landscape.

Key Points: 
  • b'The "Sphingosine 1 Phosphate Receptor Modulators - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Sphingosine 1 phosphate receptor modulators - Pipeline Insight, 2021 report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Sphingosine 1 phosphate receptor modulators pipeline landscape.
  • The drug is currently in phase 3 of clinical trials for the treatment of Atopic dermatitis; Ulcerative colitis.\nSphingosine 1 phosphate receptor modulators: Therapeutic Assessment\nThis segment of the report provides insights about the different Sphingosine 1 phosphate receptor modulators drugs segregated based on following parameters that define the scope of the report, such as:\nThere are approx.
  • The companies which have their Sphingosine 1 phosphate receptor modulators drug candidates in the most advanced stage, i.e.
  • phase III include, Arena Pharmaceuticals.\nSphingosine 1 phosphate receptor modulators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.\n'

2020 Global Multiple Sclerosis Market and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 3, 2020
Health, Pharmaceutical, Multiple sclerosis, Organ systems, Autoimmune diseases, Neurological disorders, Clinical medicine, Medical specialties, Management of multiple sclerosis, Sphingosine-1-phosphate receptor modulator, Ublituximab

The "Global Multiple Sclerosis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Multiple Sclerosis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into the Multiple Sclerosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Multiple Sclerosis treatment options, Multiple Sclerosis late stage clinical trials pipeline, Multiple Sclerosis prevalence by countries, Multiple Sclerosis market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Multiple Sclerosis pipeline: Find out drugs in clinical trials for the treatment of Multiple Sclerosis by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Multiple Sclerosis drugs: Identify key drugs marketed and prescribed for Multiple Sclerosis in the US, including trade name, molecule name, and company
    Multiple Sclerosis market valuations: Find out the market size for Multiple Sclerosis drugs in 2019 by countries.

Global Immunosuppressant Drugs Market 2020-2025 with COVID-19 Impact Analysis and Profilings of 16 Major Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 27, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Clinical medicine, RTT, Transplantation medicine, Organ transplantation, Autoinflammatory syndromes, Immunosuppressive drug, Autoimmune disease, Calcineurin, Sphingosine-1-phosphate receptor modulator, Transplant rejection

The Global Immunosuppressant Drugs Market is segmented based on Drug Class, Application, Distribution Channel, End User, and Geography.

Key Points: 
  • The Global Immunosuppressant Drugs Market is segmented based on Drug Class, Application, Distribution Channel, End User, and Geography.
  • Calcineurin inhibitors drugs are expected to hold a major share in the Global Immunosuppressant Drugs Market.
  • By application, Global Immunosuppressant Drugs Market is classified as autoimmune disease treatment, Organ Transplant and other applications.
  • North America region has the largest market share in the Global Immunosuppressant Drugs Market owing to an increasing number of cases with autoimmune disease and an increasing number of organ transplants.

Multiple Sclerosis Drugs Industry Assessment 2020: Immunomodulators, Immunosuppressants, Interferons and Others

Retrieved on: 
Tuesday, April 21, 2020
Autoimmune diseases, Organ systems, Neurological disorders, Medical specialties, Multiple sclerosis, Management of multiple sclerosis, Biology, Sphingosine-1-phosphate receptor modulator, Corinne Goldsmith Dickinson Center for Multiple Sclerosis

The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization.

Key Points: 
  • The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization.
  • The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of multiple sclerosis drugs market.
  • The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market.
  • In order to provide better and effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis.

US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

Retrieved on: 
Thursday, June 6, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, FDA, Multiple sclerosis, Chemical compounds, Chemistry, Organic chemistry, Ozanimod, Sphingosine-1-phosphate, Myelin, Multiple sclerosis drug pipeline, Sphingosine-1-phosphate receptor modulator

The European Medicines Agency (EMA) also accepted for review the Marketing Authorization Application for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) in the European Union.

Key Points: 
  • The European Medicines Agency (EMA) also accepted for review the Marketing Authorization Application for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) in the European Union.
  • Both applications are based primarily on ozanimod data from the SUNBEAM and RADIANCE Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials.
  • We believe that ozanimod has the potential to be an important option early in the treatment of relapsing forms of MS and a best-in-class S1P receptor modulator.
  • Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves.

Global Multiple Sclerosis Dynamic Market 2018-2026: Gilenya Sales will be Affected by Erosion of Generics and Launch in the Market of the Second Generation of S1P Receptor Modulators

Retrieved on: 
Monday, February 4, 2019
Lipids, Sphingosine-1-phosphate, Immunosuppressants, Multiple sclerosis, Fingolimod, Sphingosine-1-phosphate receptor modulator

The "Multiple Sclerosis: Dynamic Market Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Sclerosis: Dynamic Market Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • Multiple Sclerosis (MS) is a rapidly evolving field in which new developments are constantly influencing the market landscape.
  • Market launch of the second generation S1P receptor modulators, with same MOA as Gilenya will increase competition.
  • Positive Phase IIb Trial Results of evobrutinib and its novel MOA could offer a new treatment option for MS patients.

Global Multiple Sclerosis Market and Competitive Landscape Report 2018

Retrieved on: 
Tuesday, October 9, 2018
Multiple sclerosis, Medicine, Immunology, Clinical medicine, Nabiximols, Sphingosine-1-phosphate receptor modulator

The "Global Multiple Sclerosis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Multiple Sclerosis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Multiple Sclerosis Market and Competitive Landscape - 2018, provides comprehensive insights into Multiple Sclerosis pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Multiple Sclerosis overview with definitions, symptoms, etiology, diagnosis, treatment options; Multiple Sclerosis pipeline insights covering late stage clinical trials pipeline; Multiple Sclerosis prevalence trends by countries; Multiple Sclerosis market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Multiple Sclerosis pipeline: Find out the drugs in clinical trials for Multiple Sclerosis by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Multiple Sclerosis epidemiology: Find out the prevalence of Multiple Sclerosis by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Multiple Sclerosis products: Identify key products marketed and prescribed for Multiple Sclerosis by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Multiple Sclerosis market size: Find out the market size for Multiple Sclerosis drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Multiple Sclerosis drug sales: Find out the sales of Multiple Sclerosis drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Multiple Sclerosis drugs sales forecast: Sales forecast for Multiple Sclerosis drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Multiple Sclerosis market share analysis: Find out the market shares of Multiple Sclerosis drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Did you know that we also offer Custom Research?